N/A
Completed N=358
An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
Glaucoma, Open-Angle · Hypertension
Source: ClinicalTrials.gov NCT01735214 ↗
Enrolled (actual)
358
Serious AEs
0.0%
Results posted
Apr 2015
Primary outcomePrimary: Change From Baseline in Intraocular Pressure (IOP) in the Right Eye — -4.5 mmHg
Summary
This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). The decision to change medications lies with the physician according to their standard practice.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Intraocular Pressure (IOP) in the Right Eye |
-4.5 | — |
| PRIMARY Change From Baseline in Intraocular Pressure (IOP) in the Left Eye |
-4.2 | — |
| SECONDARY Patient Assessment of Overall Tolerability With New Treatment Using a 4-Point Scale |
48.6; 31.6; 6.1; 1.7; 12.0 | — |
| SECONDARY Physician Assessment of Tolerability With New Treatment Using a 4-Point Scale |
50.0; 33.0; 4.7; 2.2; 10.1 | — |
| SECONDARY Percentage of Participants Who Discontinue the Use of New Treatment Prior to 12 Weeks |
7.5 | — |
| SECONDARY Percentage of Participants Who Continue the New Treatment After 12 Weeks |
83.5 | — |
| SECONDARY Physician Assessment of Adherence to New Treatment Using a 4-Point Scale |
1.68; 4.47; 42.74; 41.34; 9.78 | — |
| SECONDARY Physician Assessment of Efficacy Using a 5-Point Scale |
24.0; 49.7; 10.9; 0.8; 4.7; 9.8 | — |
| SECONDARY Percentage of Participants Reaching Individual IOP Target After 12 Weeks |
49.7 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of primary open angle glaucoma (POAG) or ocular hypertension (OHT)
- Previously prescribed any IOP-lowering therapy which has been stopped and a new prostaglandin analogue -containing IOP-lowering therapy started
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT01735214). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.